PL3880204T3 - Ulepszone sposoby syntetyczne wytwarzania sprzężonych związków heterocyklicznych jako modulatorów receptora oreksyny - Google Patents

Ulepszone sposoby syntetyczne wytwarzania sprzężonych związków heterocyklicznych jako modulatorów receptora oreksyny

Info

Publication number
PL3880204T3
PL3880204T3 PL19885791.4T PL19885791T PL3880204T3 PL 3880204 T3 PL3880204 T3 PL 3880204T3 PL 19885791 T PL19885791 T PL 19885791T PL 3880204 T3 PL3880204 T3 PL 3880204T3
Authority
PL
Poland
Prior art keywords
synthetic methods
heterocyclic compounds
receptor modulators
fused heterocyclic
orexin receptor
Prior art date
Application number
PL19885791.4T
Other languages
English (en)
Inventor
Dominique Paul Michel DEPRÉ
Kiran MATCHA
Andy Josephina Joannes HUYGAERTS
Luc Jozef Raphael Moens
Dinesh Gala
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL3880204T3 publication Critical patent/PL3880204T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL19885791.4T 2018-11-14 2019-11-11 Ulepszone sposoby syntetyczne wytwarzania sprzężonych związków heterocyklicznych jako modulatorów receptora oreksyny PL3880204T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760995P 2018-11-14 2018-11-14
PCT/IB2019/059677 WO2020100011A1 (en) 2018-11-14 2019-11-11 Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators

Publications (1)

Publication Number Publication Date
PL3880204T3 true PL3880204T3 (pl) 2024-09-09

Family

ID=70730771

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19885791.4T PL3880204T3 (pl) 2018-11-14 2019-11-11 Ulepszone sposoby syntetyczne wytwarzania sprzężonych związków heterocyklicznych jako modulatorów receptora oreksyny

Country Status (26)

Country Link
US (1) US12030887B2 (pl)
EP (2) EP3880204B1 (pl)
JP (1) JP7398452B2 (pl)
KR (1) KR102777062B1 (pl)
CN (1) CN113038952B (pl)
AR (1) AR117074A1 (pl)
AU (1) AU2019380072B2 (pl)
BR (1) BR112021009211A2 (pl)
CR (1) CR20210240A (pl)
EA (1) EA202191356A1 (pl)
EC (1) ECSP21034253A (pl)
ES (2) ES3060483T3 (pl)
HR (1) HRP20240743T1 (pl)
HU (1) HUE066708T2 (pl)
IL (1) IL283067A (pl)
JO (1) JOP20210110A1 (pl)
MA (2) MA54250A (pl)
MX (1) MX2021005698A (pl)
PE (1) PE20211470A1 (pl)
PH (1) PH12021551054A1 (pl)
PL (1) PL3880204T3 (pl)
RS (1) RS65638B1 (pl)
SG (1) SG11202104886YA (pl)
SM (1) SMT202400265T1 (pl)
TW (1) TW202039452A (pl)
WO (1) WO2020100011A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022194122A1 (zh) * 2021-03-16 2022-09-22 上海翰森生物医药科技有限公司 含氮杂环的多环化合物及其制备方法和应用
AU2023340064A1 (en) * 2022-09-14 2025-03-20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Free base crystal form of polycyclic compound of nitrogen-containing heterocycle, and preparation method therefor
TW202440545A (zh) * 2022-12-12 2024-10-16 大陸商江蘇恩華藥業股份有限公司 取代四氫環戊基〔c〕吡咯衍生物、製備方法、中間體及其用途
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators
AU2024305901A1 (en) 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant
WO2025242852A1 (en) 2024-05-24 2025-11-27 Janssen Pharmaceutica Nv Seltorexant for use in treating major depressive disorder with insomnia symptoms
CN118598880B (zh) * 2024-08-07 2024-11-26 艾斯拓康生物医药(天津)有限公司 一类含氮桥环化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
US20060258691A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668811A1 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
CA2709514A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
WO2011050202A1 (en) * 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2012145581A1 (en) * 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
WO2015150252A1 (en) 2014-04-01 2015-10-08 Bayer Cropscience Ag Use of heterocyclic compounds for controlling nematodes
WO2016100157A2 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
EP3287454B1 (en) * 2015-04-24 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
MD3426251T2 (ro) 2016-03-10 2022-09-30 Janssen Pharmaceutica Nv Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists

Also Published As

Publication number Publication date
EP4428136A3 (en) 2024-11-06
US12030887B2 (en) 2024-07-09
AR117074A1 (es) 2021-07-07
CN113038952A (zh) 2021-06-25
ES3060483T3 (en) 2026-03-26
KR102777062B1 (ko) 2025-03-05
WO2020100011A1 (en) 2020-05-22
IL283067A (en) 2021-06-30
JOP20210110A1 (ar) 2021-05-16
MA71707A (fr) 2025-05-30
EP4428136C0 (en) 2025-11-26
TW202039452A (zh) 2020-11-01
EP3880204A1 (en) 2021-09-22
CR20210240A (es) 2021-06-08
SMT202400265T1 (it) 2024-07-09
EP3880204B1 (en) 2024-05-15
JP7398452B2 (ja) 2023-12-14
EP3880204C0 (en) 2024-05-15
EP3880204A4 (en) 2022-08-17
BR112021009211A2 (pt) 2021-08-03
CN113038952B (zh) 2024-08-23
KR20210091726A (ko) 2021-07-22
CA3118734A1 (en) 2020-05-22
JP2022507361A (ja) 2022-01-18
AU2019380072B2 (en) 2025-03-27
US20220009932A1 (en) 2022-01-13
MX2021005698A (es) 2021-07-07
ES2988132T3 (es) 2024-11-19
MA54250A (fr) 2022-02-23
EP4428136A2 (en) 2024-09-11
HUE066708T2 (hu) 2024-09-28
EP4428136B1 (en) 2025-11-26
EA202191356A1 (ru) 2021-08-11
HRP20240743T1 (hr) 2024-08-30
RS65638B1 (sr) 2024-07-31
AU2019380072A1 (en) 2021-05-27
SG11202104886YA (en) 2021-06-29
ECSP21034253A (es) 2021-06-30
PH12021551054A1 (en) 2021-12-06
PE20211470A1 (es) 2021-08-05

Similar Documents

Publication Publication Date Title
IL283067A (en) Improved synthetic methods for the preparation of condensed heterocyclic compounds as orexin receptor modulators
IL282916A (en) Compressed ring compounds
IL280797A (en) fused ring compounds
IL274321A (en) Bridged bicyclic compounds as farnesoid X receptor modulators
IL279592A (en) Synthesis of converted heterocyclic compressed gamma-carbolines
ZA201800388B (en) Bicyclic¿fused heteroaryl or aryl compounds as irak4 modulators
SG11202108792WA (en) Substituted bicyclic compounds as farnesoid x receptor modulators
IL285630A (en) Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
IL315005B2 (en) Synthesis of condensed gamma-carbolines and converted heterocycles
IL274322A (en) Spirocyclic compounds as paranoid X receptor modulators
SG10202101105XA (en) Charged depth filtration of antigen-binding proteins
IL266184B (en) Cyclic condensed pyridine compounds and their use as ampa receptor modulators
IL283963A (en) Synthesis of inverted heterocyclic compressed gamma-carbolines
IL273237A (en) Novel heterocyclic compounds as MGLUR7 modulators
SG11202108796YA (en) Substituted bicyclic compounds as farnesoid x receptor modulators
IL282359A (en) Methods for the preparation of lysate from fermentations
SG11202101499UA (en) Heterocyclic compounds as ahr modulators
IL266183B (en) Fused azaheterocyclic compounds and their use as ampa receptor modulators
IL262448B (en) Disubstituted heterocyclic bicyclic compounds
SI4103566T1 (sl) Kondenzirane pirimidin spojine kot modulatorji kcc2
EP3534888A4 (en) SUBSTITUTED BICYCLIC HETEROARYL-ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
IL285570A (en) Bicyclic compounds substituted as farnesoid receptor modulators
IL270966A (en) Fused bicyclic compounds
HK40034433A (en) Bridged bicyclic compounds as farnesoid x receptor modulators
HK40026053A (en) Fused bicyclic compounds